Publications
Detailed Information
The Anti-inflammatory Effect of Subconjunctival Bevacizumab on Chemically Burned Rat Corneas
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Joo Youn | - |
dc.contributor.author | Kim, Mee Kum | - |
dc.contributor.author | Shin, Mi Sun | - |
dc.contributor.author | Lee, Hyun Ju | - |
dc.contributor.author | Wee, Won Ryang | - |
dc.contributor.author | Lee, Jin Hak | - |
dc.date.accessioned | 2012-07-02T02:05:41Z | - |
dc.date.available | 2012-07-02T02:05:41Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | CURRENT EYE RESEARCH; Vol.34 2; 85-91 | ko_KR |
dc.identifier.issn | 0271-3683 | - |
dc.identifier.uri | https://hdl.handle.net/10371/78052 | - |
dc.description.abstract | Purpose: To investigate the effect of bevacizumab in a model of corneal inflammation. Materials and Methods: Epithelium from the cornea and limbus was completely removed using 100% alcohol in rats. Bevacizumab (1.25 mg/0.05 ml) or normal saline was subconjunctivally injected. One week later, corneas were examined and subjected to hematoxylin-eosin and immunofluorescent staining for VEGF. Expression of IL-2, IFN-, IL-6, and TGF- 1 were analyzed by ELISA. Results: Bevacizumab showed a borderline reduction in corneal neovascularization (11.0 4.8% and 18.0 10.0% in the bevacizumab and control groups, respectively; p = 0.054), while the extent of epithelialization was not affected (5.0 3.4% and 6.1 5.2% in the bevacizumab and control groups, respectively; p = 0.715). The infiltration of inflammatory cells was reduced (99.3 22.3 cells/ 400 in the bevacizumab-injected corneas and 182.3 58.0 cells/ 400 in the controls; p = 0.013). The levels of IL-2, IFN-, and IL-6 were decreased in the rats with the bevacizumab injections (44 6 and 79 9 pg/ml for IL-2 in the bevacizumab-injected group and control, respectively, p = 0.025; 45 5 and 67 6 pg/ml for IFN- in the bevacizumab-injected group and controls, respectively, p = 0.043; 45 6 and 75 8 pg/ml for IL-6 in the bevacizumab-injected group and controls, respectively, p = 0.030). Conclusions: Bavacizumab showed a reduction in inflammatory cell infiltration and cytokines in chemically burned rat corneas. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | INFORMA HEALTHCARE | ko_KR |
dc.subject | angiogenesis | ko_KR |
dc.subject | inflammation | ko_KR |
dc.subject | epithelium | ko_KR |
dc.subject | bevacizumab | ko_KR |
dc.subject | cornea | ko_KR |
dc.title | The Anti-inflammatory Effect of Subconjunctival Bevacizumab on Chemically Burned Rat Corneas | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 오주윤 | - |
dc.contributor.AlternativeAuthor | 김미금 | - |
dc.contributor.AlternativeAuthor | 신미선 | - |
dc.contributor.AlternativeAuthor | 이현주 | - |
dc.contributor.AlternativeAuthor | 이진학 | - |
dc.contributor.AlternativeAuthor | 위원량 | - |
dc.identifier.doi | 10.1080/02713680802607740 | - |
dc.citation.journaltitle | CURRENT EYE RESEARCH | - |
dc.description.citedreference | Carrasco MA, 2008, CORNEA, V27, P743 | - |
dc.description.citedreference | Yoeruek E, 2008, ACTA OPHTHALMOL, V86, P322, DOI 10.1111/j.1600-0420.2007.01049.x | - |
dc.description.citedreference | Kriechbaum K, 2008, BRIT J OPHTHALMOL, V92, P518, DOI 10.1136/bjo.2007.127282 | - |
dc.description.citedreference | Oh JY, 2008, STEM CELLS, V26, P1047, DOI 10.1634/stemcells.2007-0737 | - |
dc.description.citedreference | Hurmeric V, 2008, CORNEA, V27, P357 | - |
dc.description.citedreference | Papathanassiou M, 2008, AM J OPHTHALMOL, V145, P424, DOI 10.1016/j.ajo.2007.11.003 | - |
dc.description.citedreference | Bahar I, 2008, CORNEA, V27, P142 | - |
dc.description.citedreference | KIM SW, 2008, OPHTHALMOLOGY, V115, pE33 | - |
dc.description.citedreference | Uy HS, 2008, CORNEA, V27, P70 | - |
dc.description.citedreference | KURUP S, 2008, ACTA OPHTHALMOL | - |
dc.description.citedreference | BAHAR I, 2008, CURR EYE RES, V33, P22 | - |
dc.description.citedreference | Hosseini H, 2007, CLIN EXP OPHTHALMOL, V35, P745, DOI 10.1111/j.1442-9071.2007.01572.x | - |
dc.description.citedreference | Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062 | - |
dc.description.citedreference | Barros LFM, 2007, AN ACAD BRAS CIENC, V79, P389 | - |
dc.description.citedreference | Coma MC, 2007, OPHTHALMOLOGY, V114, P1574, DOI 10.1016/j.ophtha.2006.11.028 | - |
dc.description.citedreference | Manzano RPA, 2007, BRIT J OPHTHALMOL, V91, P804, DOI 10.1136/bjo.2006.107912 | - |
dc.description.citedreference | Bock F, 2007, INVEST OPHTH VIS SCI, V48, P2545, DOI 10.1167/iovs.06-0570 | - |
dc.description.citedreference | Cursiefen C, 2006, CORNEA, V25, P443 | - |
dc.description.citedreference | AZAR DT, 2006, T AM OPHTHAL SOC, V104, P264 | - |
dc.description.citedreference | MOSHFEGHI AA, 2006, OPHTHALMOLOGY, V113, pE1, DOI DOI 10.1016/J.OPHTHA.2006.05.070 | - |
dc.description.citedreference | Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465 | - |
dc.description.citedreference | DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082 | - |
dc.description.tc | 11 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.